Traders sold shares of Chemours Company (The) (NYSE:CC) on strength during trading on Monday. $25.02 million flowed into the stock on the tick-up and $65.50 million flowed out of the stock on the tick-down, for a money net flow of $40.48 million out of the stock. Of all stocks tracked, Chemours Company (The) had the 11th highest net out-flow for the day. Chemours Company (The) traded up $0.75 for the day and closed at $47.09

A number of analysts have recently issued reports on the company. UBS AG reiterated a “sell” rating and set a $36.00 target price (up previously from $35.00) on shares of Chemours Company (The) in a report on Wednesday, June 14th. Susquehanna Bancshares Inc boosted their target price on Chemours Company (The) from $45.00 to $55.00 and gave the stock a “positive” rating in a report on Monday, May 15th. Zacks Investment Research cut Chemours Company (The) from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. J P Morgan Chase & Co boosted their target price on Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a report on Friday, August 4th. Finally, Jefferies Group LLC boosted their target price on Chemours Company (The) to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Chemours Company (The) currently has an average rating of “Buy” and an average target price of $51.50.

The company has a market capitalization of $8.70 billion, a PE ratio of 30.82 and a beta of 3.63. The firm has a 50-day moving average price of $43.84 and a 200-day moving average price of $38.39.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.02. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.27 EPS. On average, equities analysts forecast that Chemours Company will post $3.51 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 17th will be issued a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date of this dividend is Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is 8.11%.

In other Chemours Company (The) news, insider Paul Kirsch sold 19,036 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $41.42, for a total value of $788,471.12. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Erich Parker sold 4,908 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $45.53, for a total value of $223,461.24. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its stake in Chemours Company (The) by 51.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 491,439 shares of the specialty chemicals company’s stock worth $10,856,000 after buying an additional 167,183 shares during the period. Teachers Advisors LLC raised its stake in Chemours Company (The) by 2.5% in the fourth quarter. Teachers Advisors LLC now owns 309,248 shares of the specialty chemicals company’s stock worth $6,831,000 after buying an additional 7,432 shares during the period. Cypress Capital Management LLC WY raised its stake in Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock worth $162,000 after buying an additional 80 shares during the period. Oakbrook Investments LLC acquired a new stake in Chemours Company (The) during the first quarter worth about $255,000. Finally, Retirement Systems of Alabama acquired a new stake in Chemours Company (The) during the first quarter worth about $9,103,000. 76.51% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/investors-sell-shares-of-chemours-company-the-cc-on-strength-cc/1488013.html.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.